• 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2020 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    April 14-18, 2020, Honolulu, HI.

    Earn up to 18 CNE hours.

     

    Find out more about it and REGISTER today!

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • ConventionCALL FOR: Podium and Poster Abstracts

    For the 38th GAPNA Annual Conference
    at the Hyatt Regency
    New Orleans, LA, September 24-26, 2020

    GAPNA members are invited to submit an abstract about their innovative work, that should enrich the APRN's knowledge and/or enhance the care of an older adult.

    Find out more info and deadline dates

  • FREE continuing education credit is available for the following session:

    "Meaningful Conversations throughout the Course of Illness"

    (session captured at the GAPNA 2018 Annual Conference)


    For November/December 2019 - Get Your Free CNE Now!

Combination Chemotherapy Increases the Risk for Adverse Events in Elderly Patients with Colorectal Cancer

About 70% of colorectal cancers (CRC) develop in patients over the age of 65.

Treatment options in these elderly patients include the use of single-agent or combination-based chemotherapies. However, elderly patients are particularly vulnerable to side effects, especially when drugs are used in combination, according to researchers.

Medicare data were used to determine what types of chemotherapy, if any, these patients received. Patients who received chemotherapy tended to be younger, had more advanced cancers, and were more likely to be married compared to patients who did not get chemotherapy.

All patients, whether receiving chemotherapy or not, had a high incidence of symptoms and laboratory test abnormalities, which increased after patients began receiving chemotherapy. Compared to patients on fluorouracil alone, those on an oxaliplatin-based regimen had higher rates of adverse events, including nausea and neuropathy.

Those 70 years of age and older were more likely to experience certain adverse events such as infection, anemia, delirium, and heart disease.

For details, see Cen et al. (2012). Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Annals of Oncology, 23(6), 1503-1511. doi:10.1093/annonc/mdr449

Related Topic 1: 

GAPNA Newsletter Issue: 

VIEW ALL ARTICLES: